Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Bundamedik Tbk's revenue for the
three
months ended in Jun. 2026 was Rp396,451 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was Rp1,624,086 Mil.
PT Bundamedik Tbk's Revenue per Share for the
three
months ended in Jun. 2026 was Rp46.08.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was Rp188.77.
During the past 12 months, the average Revenue per Share Growth Rate of PT Bundamedik Tbk was 6.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, PT Bundamedik Tbk's highest 3-Year average Revenue per Share Growth Rate was 57.30% per year. The lowest was -18.60% per year. And the median was 9.00% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
PT Bundamedik Tbk Revenue Related Terms
PT Bundamedik Tbk Revenue Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's Revenue distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp1,624,086 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk (ISX:BMHS) has a Revenue of Rp1,624,086 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Bundamedik Tbk and its competitors.
Is PT Bundamedik Tbk's Revenue too high?
PT Bundamedik Tbk's current Revenue is Rp1,624,086 Mil. Overall, PT Bundamedik Tbk has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's Revenue compare to HCA and THC?
PT Bundamedik Tbk's Revenue of Rp1,624,086 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Bundamedik Tbk and its competitors. PT Bundamedik Tbk's current Revenue is Rp1,624,086 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp263.63, compared to a current price of Rp189.00 — trading 28.3% below its estimated fair value. The current Revenue is Rp1,624,086 Mil. PT Bundamedik Tbk's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current Revenue is Rp1,624,086 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp189.00 is trading 28.3% below its estimated GF Value™ of Rp263.63.
GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.
Key valuation signals for ISX:BMHS:
Revenue: Rp1,624,086 Mil
GF Value™: Rp263.63 vs. price of Rp189.00 (28.3% below fair value)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
67GF Score
Get the complete analysis for ISX:BMHS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
